Difference between revisions of "Juvenile myelomonocytic leukemia"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "(NCT[0-9]{8})" to "[https://clinicaltrials.gov/ct2/show/$1 Clinical Trial Registry]") |
Warner-admin (talk | contribs) m (Text replacement - "clinicaltrials.gov/ct2/show" to "clinicaltrials.gov/study") |
||
| Line 33: | Line 33: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # '''AZA-JMML-001:''' Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. [https://doi.org/10.1182/bloodadvances.2020004144 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8341358/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34297046/ PubMed] [https://clinicaltrials.gov/ | + | # '''AZA-JMML-001:''' Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. [https://doi.org/10.1182/bloodadvances.2020004144 link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8341358/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/34297046/ PubMed] [https://clinicaltrials.gov/study/NCT02447666 Clinical Trial Registry] |
[[Category:Juvenile myelomonocytic leukemia regimens]] | [[Category:Juvenile myelomonocytic leukemia regimens]] | ||
Revision as of 01:30, 25 June 2023
1 regimens on this page
1 variants on this page
|
First-line therapy
Azacitidine monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Niemeyer et al. 2021 (AZA-JMML-001) | 2015-2017 | Phase 2, <20 pts (RT) |
References
- AZA-JMML-001: Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. link to original article link to PMC article PubMed Clinical Trial Registry